Jeremy is a venture partner as well as CEO of Versant's Inception Sciences Discovery Engine. He brings significant expertise in the development and translation of novel therapies.
Jeremy previously was executive vice president and chief scientific officer of Ardelyx Inc. (NASDAQ: ARDX), where he led the advancement of multiple clinical candidates. He also served as vice president and head of RNA therapeutics, lead discovery and protein sciences for Merck Research Laboratories. Before that, he led the integration of legacy Merck and Schering Plough discovery and preclinical functions as the founding head of strategic operations.
Prior to joining Merck in 2008, Jeremy was the executive director of molecular and cellular biology, lead discovery and genomics at the Genomics Institute of the Novartis Research Foundation (GNF).
Jeremy received a B.S. in molecular and cellular biology from the University of California at Berkeley and a Ph.D. in molecular pharmacology from Stanford University.